Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rockwell MedicalFRA:RWM 55 3-Year EBITDA Growth Rate is 63.40% as of Jun. 2026, which is 214% above its 10-year median of 20.20. GuruFocus rates FRA:RWM with a GF Score™ of 55/100 and a GF Value™ of €5.73 (Fairly Valued). The stock has 2 warning signs investors should review. Among 809 Drug Manufacturers companies, Rockwell Medical ranks better than 91.97% on this metric.
During the past 12 months, Rockwell Medical's average EBITDA Per Share Growth Rate was -222.90% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 63.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Rockwell Medical was 63.40% per year. The lowest was -165.20% per year. And the median was 20.20% per year.
Rockwell Medical (FRA:RWM) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Rockwell Medical 3-Year EBITDA Growth Rate Related Terms
FRA:RWM vs BTAI, MRMD, TXMD: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rockwell Medical 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Rockwell Medical's 3-Year EBITDA Growth Rate falls into.
Rockwell Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 63.40% mean?
Rockwell Medical (FRA:RWM) has a 3-Year EBITDA Growth Rate of 63.40% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rockwell Medical and its competitors. This is 214% above median its historical median of 20.20. According to the industry distribution chart, Rockwell Medical ranks #65 out of 809 companies in the Drug Manufacturers industry, placing it in the top 8%.
Is Rockwell Medical's 3-Year EBITDA Growth Rate too high?
Rockwell Medical's current 3-Year EBITDA Growth Rate of 63.40% is 214% above median its 10-year median of 20.20. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Rockwell Medical's value of 63.40% is 612.4% above this industry median. Based on the distribution chart, Rockwell Medical ranks #65 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rockwell Medical has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's 3-Year EBITDA Growth Rate compare to BTAI and MRMD?
According to the Drug Manufacturers industry distribution chart, Rockwell Medical ranks #65 out of 809 companies for 3-Year EBITDA Growth Rate. This places Rockwell Medical in the top 8% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Rockwell Medical's value of 63.40% is 612.4% above this benchmark. While the company's 10-year median is 20.20 vs. the industry median of 8.90, Rockwell Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rockwell Medical's current 3-Year EBITDA Growth Rate of 63.40% is 612.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Rockwell Medical and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rockwell Medical's current 3-Year EBITDA Growth Rate is 63.40%, which is 214% above median its own 10-year median of 20.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Fairly Valued. The stock's GF Value™ is €5.73, compared to a current price of €5.25 — trading 8.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 63.40%, which is 214% above median its 10-year median of 20.20 and 612.4% above the Drug Manufacturers industry median of 8.90. Rockwell Medical's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current 3-Year EBITDA Growth Rate is 63.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rockwell Medical (FRA:RWM) Overvalued in 2026?
Based on GuruFocus' analysis, Rockwell Medical stock appears to be undervalued.
The current stock price of €5.25 is trading 8.4% below its estimated GF Value™ of €5.73.
GuruFocus considers Rockwell Medical to be Fairly Valued.
Key valuation signals for FRA:RWM:
3-Year EBITDA Growth Rate: 63.40% (214% above median its 10-year median of 20.20)
GF Value™: €5.73 vs. price of €5.25 (8.4% below fair value)
Industry Position: 612.4% above the Drug Manufacturers median (#65 of 809)
No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
55GF Score
Get the complete analysis for FRA:RWM
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RWM has been successfully added to your 
